Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 10 May 2022
First treatment option indicated for CKD in Scotland for 20 years
10 May 2022 - NICE recommendation for Forxiga could entitle 53,000 adults to the new kidney disease therapy ...
Posted by Michael Wonder on 10 May 2022
High-risk COVID-19 patients can now get two antiviral prescription drugs — but some are still missing out
10 May 2022 - For Australians at high risk of developing severe COVID-19, getting access to potentially lifesaving treatment recently ...
Posted by Michael Wonder on 10 May 2022
Eisai completes rolling submission to the U.S. FDA for biologics license application of lecanemab for early Alzheimer's disease under the accelerated approval pathway
10 May 2022 - Eisai and Biogen announced today that Eisai has completed the rolling submission to the U.S. FDA of ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...
Posted by Michael Wonder on 09 May 2022
The Center for Medicare and Medicaid Innovation - toward value based care
9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Blenrep in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). ...
Posted by Michael Wonder on 09 May 2022
SMC - May 2022 decisions
9 May 2022 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 09 May 2022
Next Health Minister must restart the National Medicines Policy Review
10 May 2022 - Medicines Australia has released a video outlining the importance of restarting the National Medicines Policy Review ...
Posted by Michael Wonder on 09 May 2022
Product information update for COVID-19 treatment Xevudy (sotrovimab)
6 May 2022 - On 7 April 2022, the TGA announced receipt of an application from GSK for a higher (1000 ...
Posted by Michael Wonder on 09 May 2022
Choices that fail health and wellbeing
5 May 2022 - NICE's expert group RAPID C-19, set up to ‘to ensure safe and timely patient access to treatments ...
Posted by Michael Wonder on 08 May 2022
Wearable technology promises to revolutionise health care
5 May 2022 - Do not let bureaucracy delay matters. ...
Posted by Michael Wonder on 08 May 2022
NHS rolls out life-saving arthritis drug to treat COVID
5 May 2022 - The NHS is rolling out a cutting-edge, life-saving COVID treatment from today, which is proven to ...
Posted by Michael Wonder on 08 May 2022
Myovant & Pfizer provide update on supplemental new drug application for Myfembree for the management of moderate to severe pain associated with endometriosis
6 May 2022 - Myovant Sciences & Pfizer announced today that the U.S. FDA has extended the review period for the ...
Posted by Michael Wonder on 08 May 2022
Supporting innovation in Medicaid policy - interventions to increase adoption of RCTs
7 May 2022 - Randomised, controlled trials remain underutilised within the Medicaid program, even though state Medicaid programs regularly implement new ...
Posted by Michael Wonder on 07 May 2022
FDA limits use of Janssen COVID-19 vaccine to certain individuals
5 May 2022 - Today, the U.S. FDA has limited the authorised use of the Janssen COVID-19 Vaccine to individuals ...